[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gastro-esophageal-reflux\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gastro-esophageal-reflux":360},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,14,0,[8,43,67,105,129,158,181,200,226,247,276,303,325,349],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100453109","esophageal-and-gastric-registry-and-biorepository-100453109",false,"NCT05180253","Esophageal and Gastric Registry and Biorepository","Healthy Control Esophageal and Gastric Registry and Biorepository","Inclusion Criteria:\n\n* Age 18-85\n* No prior surgical history\n* Asymptomatic according to gastroesophageal and gastric questionnaires\n* Not currently taking any medications that affect acid secretion or gut motility\n* No history of malignancy\n* No mental health issues precluding informed consent\n* No smoking history\n* No excessive or daily alcohol use\n* BMI \\\u003C 30\n* No known hiatus hernia\n* No known medical illness (autoimmune, neurological) that could be associated with altered esophageal or gastric function\n* Not allergic to fentanyl or versed\n* No history of eating disorder\n* No history of autoimmune disorders\n\nExclusion Criteria:\n\n* Minors\n* Surgeries involving the GI tract\n* Medication use affecting acid secretion or gut motility\n* Personal history of malignancy\n* Mental health issues precluding informed consent\n* Symptoms on standard clinical questionnaires\n* Pregnant - the effect that pregnancy has on esophageal and gastric motility is not well defined, but we will need to eliminate this as a confounding factor\n* Nursing women - although the investigations are FDA approved and part of standard clinic practices, they are time consuming and involve medication administration that might affect the ability of a mother to nurse",true,"ALL","18 Years","85 Years",{"count":21,"type":22},40,"ESTIMATED","OBSERVATIONAL","The evaluation of the foregut, the esophagus and stomach, has come a long way over the past two decades, and continues to experience exciting discoveries in the clinical evaluation of foregut physiology. Assessing esophageal peristalsis has relied for the past several decades on High Resolution Manometry (HRM), however it has recently become known that even though HRM is an extremely effective tool, that there are certain subsets of patients in which additional information is required. Additionally, the assessment of esophageal reflux disease has relied on pH impedance for the last two decades. However, this procedure requires a catheter to be passed through a nostril and remain in place for at least 24 hours. Novel techniques, already FDA approved, including EndoFLIP for esophageal peristalsis and mucosal integrity (MI) for reflux disease, have emerged as time-of-endoscopy assessments. Both involve the placement of a balloon through the scope at time of upper endoscopy (standard first line assessment for both dysphagia and reflux symptoms) and are quick and pose little-to-no additional risk or discomfort for patients. However, data regarding normal esophageal parameters are poorly defined for both EndoFLIP and MI. Additionally, EndoFLIP has increasingly been used to assess the pylorus, and scarce data exists there regarding how a tool originally envisioned for esophageal assessment can be used more distally in the GI tract.\n\nWe will recruit healthy, asymptomatic volunteers to undergo testing with MI and FLIP (esophageal and pyloric). The data obtained will help establish the benchmark from which assessments can be made in patients.",[26],"Gastro Esophageal Reflux",[28,29],"Mucosal Integrity","Functional Luminal Imaging Probe","RECRUITING","2026-04-28",{"date":33,"type":34},"2026-05-04","ACTUAL",{"date":36,"type":34},"2023-01-09",{"date":38,"type":22},"2026-06",{"name":40,"class":41},"University of Louisville","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":42},"100400424","endoscopic-bariatric-therapies-ebts-a-retrospective-and-prospective-multicenter-registry-100400424","NCT04494048","Endoscopic Bariatric Therapies (EBTs): A Retrospective and Prospective Multicenter Registry","EBT","Inclusion Criteria:\n\n* Any patient who is considering undergoing EBT for weight loss within 6 months, or has undergone clinically indicated EBT for weight loss within the past 6 months\n* Above or equal to 18 years of age.\n\nExclusion Criteria:\n\n* Any patient who has not undergone or will undergo EBT for weight loss\n* Below 18 years of age.","89 Years",{"count":52,"type":22},9999,"The purpose of this registry study is to collect data through medical chart review and in patient visits on the efficacy and safety of various Endoscopic Bariatric therapies (EBTs). This is a retrospective and prospective, observational, medical chart review study for at least 6 standard of care visits up to 1 years after a subject consents for study participation.",[55,56,26,57],"Obesity","Weight Loss","Bariatric Surgery Candidate","2026-04-21",{"date":60,"type":34},"2026-04-23",{"date":62,"type":34},"2016-04-05",{"date":64,"type":22},"2035-10-31",{"name":66,"class":41},"Weill Medical College of Cornell University",{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":17,"minAge":74,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":89,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":104},"100515299","validation-of-the-c-mo-system---cough-monitoring-100515299","NCT05989698","Validation of the C-mo System - Cough Monitoring","C-mo_01","Inclusion Criteria:\n\n* Patients aged 2 years or older;\n* Patients with symptoms\u002Fcomplaints of cough;\n* Signed Informed Consent (age ≥ 18 years), signed Informed Consent from the parents\u002Flegal representative and the patient (16 and 17 years), or signed Informed Assent and Consent (5 years ≤ age ≤ 15 years).\n\nExclusion Criteria:\n\n* Presence of musculoskeletal (e.g., severe scoliosis), neurological (e.g., post stroke), cardiac (e.g., unstable angina), cognitive (e.g., dementia) changes, or other significant conditions that hinder the participants from collaborating in the collection of data.\n* Damaged\u002Fweakened skin at the C-mo wearable device's placement area (epigastric region).\n* Absence of Informed Consent and\u002For Assent, as applicable.","2 Years",{"count":76,"type":22},300,"INTERVENTIONAL",[79],"NA","The goal of this clinical study is to validate C-mo System's ability to automatically detect and characterise cough, in patients over 2 years old with cough as a key or refractory symptom.\n\nThe main questions it aims to answer are:\n\n1. Can C-mo System detect cough events? (automatic cough detection)\n2. Can C-mo System characterise cough events? (calculation of cough intensity, identification of cough type and presence of wheeze in detected coughs)\n\nParticipants will be asked to:\n\n* Wear the C-mo Wearable device for 24 hours (1 day);\n* Complete a diary with relevant activities throughout the monitoring period;\n* Fill-out questionnaires related to coughing frequency and intensity, usability of the device, and impact of cough on quality of life.",[82,83,84,26,85,86,87,88],"Cough","Asthma","Chronic Obstructive Pulmonary Disease","Idiopathic Pulmonary Fibrosis","Cough Frequency","Cough Severity","Coughing",[90,91,92,93],"Cough monitoring","Cough detection","Cough assessment","C-mo","2026-04-02",{"date":96,"type":34},"2026-04-08",{"date":98,"type":34},"2023-12-11",{"date":100,"type":22},"2026-09",{"name":102,"class":103},"Cough Monitoring Medical Solutions","INDUSTRY",8,{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":112,"targetDuration":114,"studyType":23,"phases":4,"briefSummary":115,"conditions":116,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":42},"100386507","clinical-utility-of-wats3d-a-5-year-prospective-study-100386507","NCT04312633","Clinical Utility of WATS3D: A 5-Year Prospective Study","CDx Study 906: The Clinical Utility of WATS3D (Wide Area Transepithelial Sampling With Computer-Assisted 3-Dimensional Analysis): A 5- Year Prospective Registry","Inclusion Criteria:\n\n* Able to read, comprehend and complete the IRB-approved consent form\n* Aged 18 or older\n* Meet one of the following:\n* Patients with heartburn or regurgitation undergoing a screening EGD, who undergo WATS3D sampling and forceps biopsies for suspicion of BE, or\n* Patients with known BE with or without dysplasia undergoing a surveillance EGD with WATS3D biopsies and forceps biopsies, or\n* Patients who have undergone endoscopic eradication (i.e. radiofrequency ablation or cryoablation) who are undergoing surveillance EGD following the establishment of complete eradication of intestinal metaplasia (CEIM)\n* Only patients who undergo both forceps biopsies and WATS3D of the esophagus will be included.\n\nExclusion Criteria:\n\n* Pregnancy at time of endoscopy\n* Unresolved drug or alcohol dependency that will limit ability to comprehend or follow instructions related to informed consent, post-treatment instructions or follow-up guidelines\n* Medical condition that will likely prohibit completion of a 5 year study",{"count":113,"type":22},90000,"5 Years","The purpose of this study is to create a registry (collect data and keep it in a research database) to learn more about two methods of taking small tissue samples from your esophagus (the esophagus is the tube that carries food and liquid from your mouth to your stomach). The two methods of sampling are: 1) Using forceps that take biopsies (small tissue samples) from your esophagus, and 2) Using a brush that also takes biopsies from your esophagus.",[117,26,118,119],"Barrett Esophagus","Esophageal Dysplasia","Esophageal Diseases","2026-03-18",{"date":122,"type":34},"2026-03-20",{"date":124,"type":34},"2020-04-01",{"date":126,"type":22},"2027-11-01",{"name":128,"class":103},"CDx Diagnostics",{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":135,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":17,"minAge":137,"maxAge":138,"enrollmentInfo":139,"targetDuration":141,"studyType":23,"phases":4,"briefSummary":142,"conditions":143,"keywords":144,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":42},"100630076","prevalence-of-symptomatic-gastroesophageal-reflux-disease-in-czech-children-czech-gerdkids-100630076","NCT07482969","Prevalence of Symptomatic Gastroesophageal Reflux Disease in Czech Children (Czech GERDKids)","Prevalence of Symptomatic Gastroesophageal Reflux Disease in Children in the Czech Republic","Czech GERDKids","Inclusion Criteria:\n\n* age group of 8 - 9 years and 12 - 13 years\n* school attendance ability\n\nExclusion Criteria:\n\n* psychomotor impairment","8 Years","13 Years",{"count":140,"type":22},1000,"3 Months","This study aims to determine the prevalence of symptomatic gastroesophageal reflux disease (GERD) in children aged 8-9 years and 12-13 years in the Czech Republic. Participants are recruited through schools and complete a web-based questionnaire assessing reflux-related symptoms. Children reporting pyrosis or regurgitation undergo a stepwise diagnostic evaluation that includes a standardized proton pump inhibitor (PPI) trial, upper endoscopy when indicated, and 24-hour pH-impedance monitoring for those with inconclusive findings. These procedures allow classification into confirmed GERD, reflux hypersensitivity, or functional pyrosis. All children undergoing diagnostic testing complete a validated quality-of-life questionnaire. The study will provide population-based prevalence estimates and evaluate symptom burden and potential risk factors associated with pediatric GERD.",[26],[145,146,147,148],"Reflux disease","Children","Prevalence","Population","2026-03-16",{"date":151,"type":34},"2026-03-19",{"date":153,"type":34},"2025-12-20",{"date":155,"type":22},"2028-12-30",{"name":157,"class":41},"University Hospital, Motol",{"id":159,"slug":160,"hasResults":11,"nctId":161,"briefTitle":162,"officialTitle":163,"acronym":164,"eligibilityCriteria":165,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":166,"enrollmentInfo":167,"targetDuration":4,"studyType":77,"phases":169,"briefSummary":170,"conditions":171,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":42},"100483085","anti-reflux-endoscopic-tx-using-apc-area-in-gerd-patients-the-area-study-100483085","NCT05570448","Anti-Reflux Endoscopic TX Using APC (AREA) in GERD Patients: (The AREA Study)","Anti-Reflux Endoscopic Therapy Using Argon Plasma Coagulation (AREA) in Gastroesophageal Reflux Disease (GERD) Patients: A Single Center, Randomized, Sham, Controlled Trial (The AREA Study)","AREA21","Inclusion Criteria:\n\n* Chronic GERD symptoms (at least 1 typical symptom of GERD, i.e. heartburn or acid reflux\u002Fregurgitation at least twice a week) for last 6 months\n* Objective evidence of reflux disease (positive ambulatory pH study.)\n\nExclusion Criteria:\n\n* Patients unable to or unwilling to participate or consent.\n* Age \\\u003C18 years or \\>80 years.\n* Allergic or intolerant to PPI medications.\n* Large hiatal hernia \\> 3 cm and Hill grade IV.\n* Barrett's esophagus.\n* Esophageal stricture with any prior intervention.\n* Major motility disorder.\n* Eosinophilic esophagitis.\n* Gastroparesis documented by abnormal gastric emptying time.\n* Previous fundoplication, myotomy or LINX surgery.\n* Cirrhosis with esophageal and\u002For gastric varices.","80 Years",{"count":168,"type":22},36,[79],"This will be a randomized clinical trial examining the efficacy and safety of ARAT (intervention group) in patients with chronic GERD symptoms (typical symptoms of GERD, i.e. heartburn or acid reflux\u002Fregurgitation at least twice a week) for the last 6 months.\n\nPatients must have a positive pH test and a negative manometry (no treatment) procedure.",[26],"2026-02-26",{"date":174,"type":34},"2026-02-27",{"date":176,"type":34},"2022-02-15",{"date":178,"type":22},"2027-04-01",{"name":180,"class":41},"Midwest Veterans' Biomedical Research Foundation",{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":185,"acronym":4,"eligibilityCriteria":186,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":187,"enrollmentInfo":188,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":189,"conditions":190,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":42},"100537656","efficacy-of-hiatal-closure-for-gerd-100537656","NCT06280664","Efficacy Of Hiatal Closure For GERD","Inclusion Criteria:\n\n* Age 18 - 50 years\n* Able to provide informed consent\n* BMI \\\u003C30\n* Hiatal defect \\\u003C4cm on esophagram\n* pH testing requirement: pH \\\u003C4 for \\>5.5%\n* Surgical candidate for hiatal closure only\n\nExclusion Criteria:\n\n* Vulnerable subjects (children, prisoners, pregnant women) will be excluded.","50 Years",{"count":21,"type":22},"The purpose of this protocol is to study the efficacy of hiatal closure for early GERD disease. The study team hypothesizes that hiatal closure for early GERD disease is an efficacious treatment of GERD.",[26],"2026-01-29",{"date":193,"type":34},"2026-02-02",{"date":195,"type":34},"2020-10-02",{"date":197,"type":22},"2028-10",{"name":199,"class":41},"University of Chicago",{"id":201,"slug":202,"hasResults":11,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":4,"eligibilityCriteria":206,"healthyVolunteers":11,"sex":17,"minAge":114,"maxAge":207,"enrollmentInfo":208,"targetDuration":4,"studyType":77,"phases":210,"briefSummary":212,"conditions":213,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":42},"100474242","phase-4-gastrointestinal-dysmotility-on-aspiration-risk-100474242","NCT05455359","Gastrointestinal Dysmotility on Aspiration Risk","The Impact of Upper Gastrointestinal Dysmotility on Aspiration-associated Symptoms","Inclusion Criteria:\n\n1. are 5-21 years of age;\n2. receive \\>90% of their calories by enteral tube (i.e., patients take no food or drink by mouth);\n3. are determined to be at high risk for aspiration pneumonia based on evidence of impaired airway protective mechanisms, documented by aspiration on video fluoroscopic swallow study;\n4. have static neurologic impairment, defined as functional and\u002For intellectual impairment that results from a chronic neurologic or related diagnosis (e.g., cerebral palsy) with no prospect of progression for at least one year;\n5. have chronic respiratory symptoms, defined as coughing, choking, or need for oral suctioning a minimum of three times per week during the prior four weeks.\n\n   \\-\n\nExclusion Criteria:\n\n1. have progressive neurologic impairment;\n2. have a history of prior intact Nissen fundoplication;\n3. are currently taking oral or inhaled antibiotics, including prophylactic antibiotics;\n4. are currently taking or have taken in the last four weeks acid suppression (H2 antagonist or PPI); or\n5. are fed by gastrojejunostomy rather than by gastrostomy. -","21 Years",{"count":209,"type":22},120,[211],"PHASE4","The hypothesis of this study is that esophageal and gastric dysmotility increase the risk of developing aspiration-associated symptoms in children with neurologic impairment. The investigators are conducting a ten week cross over study comparing prucalopride to famotidine for the treatment of aspiration-associated symptoms.",[214,215,216,26],"Esophageal Motility Disorders","Gastric Motor Dysfunction","Aspiration Pneumonia","2025-12-23",{"date":219,"type":34},"2025-12-26",{"date":221,"type":34},"2025-02-13",{"date":223,"type":22},"2027-05-31",{"name":225,"class":41},"Boston Children's Hospital",{"id":227,"slug":228,"hasResults":11,"nctId":229,"briefTitle":230,"officialTitle":230,"acronym":4,"eligibilityCriteria":231,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":232,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":234,"conditions":235,"keywords":4,"overallStatus":237,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":245,"locationsCount":4},"100608286","association-between-obesity-and-gastroesophageal-reflux-disease-100608286","NCT07199582","Association Between Obesity and Gastroesophageal Reflux Disease","Inclusion Criteria:\n\n* Age ≥18 years old. Obese patients (BMI ≥30 Kg\u002Fm2).\n\nExclusion Criteria:\n\n* · Eosinophilic esophagitis.\n\n  * Achalasia.\n  * Esophageal cancer. Stomach cancer.",{"count":233,"type":22},200,"Gastroesophageal reflux disease (GERD) is a chronic disorder marked by heartburn and regurgitation, resulting from the reflux of gastric acid or bile into the esophagus. Chronic acid exposure leads to mucosal inflammation, erosive esophagitis, and Barrett's esophagus, conditions that increase the risk of esophageal adenocarcinoma (Badreddine RJ et al., 2010; Fass R, 2022). Obesity, defined by the World Health Organization as a body mass index (BMI) ≥30 kg\u002Fm², is recognized as a major global public health issue due to its rapidly rising prevalence and strong association with chronic disease. It is not only a cause of metabolic disorders but also a driver of systemic health complications (WHO, 2024). Obesity is linked with type 2 diabetes, cardiovascular disease, hypertension, non-alcoholic fatty liver disease, certain cancers, and sleep apnea.\n\nAdditionally, it negatively impacts psychological well-being, contributing to depression, low self-esteem, and social stigma (CDC, 2024). Evidence suggests a strong link between obesity and GERD. Studies demonstrate that obese individuals exhibit higher intra-gastric pressure, delayed esophageal transit, increased esophageal acid exposure, and a greater prevalence of defective lower esophageal sphincter function. These pathophysiological mechanisms contribute significantly to GERD development and its complications (de Vries DR et al., 2008; Cote-Daigneault J et al., 2014; Anggiansah R et al., 2013; Ayazi S et al., 2009). The rationale for this study is to explore the relationship between obesity and GERD, given the rising prevalence of obesity and its implications for gastrointestinal health. Diagnosis of GERD is primarily clinical, based on symptoms such as heartburn and regurgitation. A trial of proton pump inhibitors for 4-8 weeks is recommended in patients without alarm features. Endoscopy is indicated for those with alarm signs or refractory disease, while pH monitoring is the gold standard in uncertain cases. Manometry is reserved for pre-surgical evaluation (Katz PO et al., 2022).To study the relationship between Obesity and GERD, given the rising prevalence of obesity and its potential impact on gastrointestinal health.",[26,236],"Obesity (Disorder)","NOT_YET_RECRUITING","2025-09-22",{"date":240,"type":34},"2025-09-30",{"date":242,"type":22},"2025-12-01",{"date":244,"type":22},"2027-02-01",{"name":246,"class":41},"Assiut University",{"id":248,"slug":249,"hasResults":11,"nctId":250,"briefTitle":251,"officialTitle":252,"acronym":253,"eligibilityCriteria":254,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":255,"enrollmentInfo":256,"targetDuration":4,"studyType":77,"phases":258,"briefSummary":259,"conditions":260,"keywords":263,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":267,"lastUpdatePostDateStruct":268,"startDateStruct":270,"completionDateStruct":272,"leadSponsor":274,"locationsCount":42},"100605091","comparison-of-nissen-sleeve-and-gastric-bypass-for-gerd-in-obese-patients-100605091","NCT07158008","Comparison of Nissen-Sleeve and Gastric Bypass for GERD in Obese Patients","The SLEEVE-GERD Trial: A Comparative Study of Nissen-Sleeve and Roux-en-Y Gastric Bypass in Obese Patients With GERD","SLEEVE-GERD","Inclusion Criteria:\n\nFor N-Sleeve Gastrectomy (N-SG) and Roux-en-Y Gastric Bypass (RYGB) arms:\n\n* Age ≥ 18 years\n* Written informed consent provided\n* Eligible for bariatric surgery according to national guidelines (BMI ≥ 40 kg\u002Fm² or BMI ≥ 35 kg\u002Fm² with obesity-related comorbidities)\n* Presence of symptomatic gastroesophageal reflux disease (GERD), defined by at least one of the following:\n* Regular use of proton pump inhibitors (PPIs)\n* GerdQ score \\> 6\n* Endoscopic evidence of esophagitis (Los Angeles classification grade B or higher)\n\nFor Sleeve Gastrectomy (SG) observational control group:\n\n* Age ≥ 18 years\n* Written informed consent provided\n* Eligible for bariatric surgery according to national guidelines (BMI ≥ 40 kg\u002Fm² or BMI ≥ 35 kg\u002Fm² with obesity-related comorbidities)\n* No symptoms or history of GERD\n\nExclusion Criteria:\n\n* History of prior anti-reflux surgery\n* History of upper gastrointestinal tract surgery\n* Active smoking or history of nicotine use\n* Severe cardiac insufficiency (New York Heart Association Class III or IV)\n* Pregnancy or planned pregnancy during the study period (if applicable based on future additions)\n* Any condition that, in the opinion of the investigator, would interfere with the participant's ability to comply with the study protocol or would pose additional risk","65 Years",{"count":257,"type":22},560,[79],"This randomized clinical trial aims to compare two surgical techniques for the treatment of obesity in patients who also have symptoms of gastroesophageal reflux disease (GERD). The study will compare Nissen-Sleeve Gastrectomy (N-SG)-a sleeve gastrectomy combined with a reflux-preventing procedure-to the Roux-en-Y Gastric Bypass (RYGB), which is the current standard surgical option for obese patients with GERD.\n\nBoth procedures are widely used to treat severe obesity, but they differ in how they affect the digestive system and the potential for reflux control, nutritional outcomes, and future surgical options. N-SG is a newer technique that preserves the natural pathway of the gastrointestinal tract and allows standard endoscopic access to the bile ducts, which may be beneficial for long-term patient care. RYGB, on the other hand, bypasses part of the stomach and small intestine, which may lead to better reflux resolution but carries risks of nutritional deficiencies and altered anatomy.\n\nEligible participants with obesity and GERD symptoms will be randomly assigned to receive either N-SG or RYGB. The primary goal is to evaluate whether N-SG is not inferior to RYGB in reducing GERD symptoms one year after surgery. Secondary outcomes include weight loss, quality of life, surgical complications, and changes in the hormone ghrelin, which is involved in appetite regulation.\n\nIn addition, a larger control group of patients without GERD undergoing standard sleeve gastrectomy will be recruited to allow further comparisons. All participants will be followed for one year after surgery, with blood samples, questionnaires, and clinical data collected to assess both metabolic and reflux-related outcomes.\n\nThis study is being conducted at the University Hospital in Kraków, Poland, and aims to improve the personalization of bariatric treatment for patients suffering from both obesity and reflux.",[26,261,262],"Severe Obesity","Bariatric Surgery",[264,265,266],"Nissen-Sleeve","Gastric Bypass","GERD","2025-08-28",{"date":269,"type":34},"2025-09-05",{"date":271,"type":34},"2025-07-31",{"date":273,"type":22},"2028-09",{"name":275,"class":41},"Jagiellonian University",{"id":277,"slug":278,"hasResults":11,"nctId":279,"briefTitle":280,"officialTitle":281,"acronym":4,"eligibilityCriteria":282,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":283,"enrollmentInfo":284,"targetDuration":4,"studyType":77,"phases":286,"briefSummary":287,"conditions":288,"keywords":289,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":294,"lastUpdatePostDateStruct":295,"startDateStruct":297,"completionDateStruct":299,"leadSponsor":301,"locationsCount":42},"100603044","the-effect-of-inspiratory-muscle-training-in-people-with-gastroesophageal-reflux-disease-100603044","NCT07131397","The Effect of Inspiratory Muscle Training in People With Gastroesophageal Reflux Disease","The Effect of Inspiratory Muscle Training on Inspiratory Strength in People With Gastroesophageal Reflux Disease.","Inclusion Criteria: people diagnosed with GERD or had a score of more than 8 on the Gastroesophageal Reflux Disease Questionnaire\n\nExclusion Criteria: systemic connective tissue diseases, mental disorders, stomach or duodenal surgery, tuberculosis, pregnancy","70 Years",{"count":285,"type":22},30,[79],"The present Randomized Control Trial will be a single centric, two arm parallel equivalence randomized controlled. Participants will be assigned to either the Inspiratory MuscleTraining (IMT) group (investigation) or to Sham IMT group (control). The assessment times were three (3) before the start of the program (baseline-T1), immediately after the 3 months of the main exercise program (end of the main program-T2) and 6 months after (end of follow up-T3).\n\nThe measurements included: A. By measuring the Maximum Inspiratory Pressure (MIP) (Micro RPM) B. By measuring the Maximum Dynamic Inspiratory Pressure s-index (Powerbrethe K5)\n\nThe following instruments were included in the secondary outcome measures:\n\n* Recurrent Gastroesophageal Reflux Disease Questionnaire (measurement of symptom frequency-RDQ Questionaire).\n* Gastroesophageal Reflux Disease-Related Quality of Life Questionnaire (Quality of Life Measure-Reflux Qual short form questionnaire).",[26],[290,291,292,293],"Inspiratory Muscle Training","Gastroesophageal Reflux Disease","Antireflux valve","Maximal Inspiratory Pressure","2025-08-15",{"date":296,"type":34},"2025-08-20",{"date":298,"type":34},"2025-01-08",{"date":300,"type":22},"2027-12-30",{"name":302,"class":41},"University of West Attica",{"id":304,"slug":305,"hasResults":11,"nctId":306,"briefTitle":307,"officialTitle":308,"acronym":4,"eligibilityCriteria":309,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":310,"enrollmentInfo":311,"targetDuration":4,"studyType":77,"phases":312,"briefSummary":313,"conditions":314,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":316,"lastUpdatePostDateStruct":317,"startDateStruct":319,"completionDateStruct":321,"leadSponsor":323,"locationsCount":42},"100559471","the-effect-of-postural-correction-on-gastroesophageal-reflux-disease-100559471","NCT06564558","The Effect of Postural Correction On Gastroesophageal Reflux Disease","The Effect of Postural Correctional Interventions on the Quality of Life of Patients With Gastroesophageal Reflux Disease.","Inclusion Criteria:\n\n* Ages between 18 and 60.\n* Diagnosed with GERD by a primary medical doctor.\n* Patients with a kyphosis angle greater than 30 degrees.\n* A score of 8 or greater on the Frequency Scale for the Symptoms of GERD (FSSG) which is considered positive.\n\nExclusion Criteria:\n\n* Individuals with recent spinal surgery.\n* Recent spinal trauma in the thoracic or lumbar regions\n* A score less than 8 on the FSSG\n* Having no associated thoracic or thoracolumbar deformity or abnormal alignment.","60 Years",{"count":285,"type":22},[79],"The main aim of this randomized controlled trial is to investigate the effects of postural correctional exercises and interventions on the severity of symptoms of gastroesophageal reflux disease (GERD) as well as the quality of life of patients afflicated with this disease. The main questions this study aims to answer is:\n\n1. Do postural correctional exercises reduce the symptoms of GERD?\n2. Do postural correctional exercises improve the quality of life of individuals afflicted with GERD?\n\nThe experimental group in this study will undergo real postural correctional exercises whereas the control group will undergo sham postural correctional interventions and then the two groups will be compared post-treatment based on GERD severity of symptoms as well as quality of life of the patients afflicted with GERD.",[26,315],"Gastro Esophageal Reflux Disease","2024-08-19",{"date":318,"type":34},"2024-08-21",{"date":320,"type":22},"2024-09-01",{"date":322,"type":22},"2025-09-01",{"name":324,"class":41},"Cairo University",{"id":326,"slug":327,"hasResults":11,"nctId":328,"briefTitle":329,"officialTitle":330,"acronym":331,"eligibilityCriteria":332,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":166,"enrollmentInfo":333,"targetDuration":114,"studyType":23,"phases":4,"briefSummary":335,"conditions":336,"keywords":337,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":340,"lastUpdatePostDateStruct":341,"startDateStruct":343,"completionDateStruct":345,"leadSponsor":347,"locationsCount":42},"100444374","observational-registry-of-transoral-incisionless-fundoplication-tif-for-gastroesophageal-reflux-disease-gerd-100444374","NCT05066594","Observational Registry of Transoral Incisionless Fundoplication (TIF) for Gastroesophageal Reflux Disease (GERD)","Observational Registry of Transoral Incisionless Fundoplication (Creation of a New Gastroesophageal Valve) in Patients With Gastroesophageal Reflux Disease","TIF\u002F2021","Inclusion Criteria for enrollment:\n\n* Clinical indication to undergo transoral incisionless fundoplication (TIF) with the EsophyX device for treatment of chronic gastro-esophageal reflux disease;\n* Availability for prolonged follow-up (5 years) after TIF at San Raffaele Hospital;\n* Signed informed consent for participation in the observational registry.\n\nExclusion Criteria for enrollment:\n\n* Absence of clinical indication to undergo transoral incisionless fundoplication (TIF) with the EsophyX device for treatment of chronic gastro-esophageal reflux disease;\n* Unavailability for prolonged follow-up (5 years) after TIF at San Raffaele Hospital;\n* No signed informed consent for participation in the observational registry.",{"count":334,"type":22},100,"This observational registry aims to: 1) record the TIF interventions in patients with esophageal or extra-esophageal symptoms; 2) to monitor the therapy response through the clinical experience in terms of effect on the use and dosage of proton pump inhibitors (PPIs) and on the GERD-Health Related Quality of Life (HRQL) and Reflux Symptom Index (RSI) questionnaires scores; 3) to characterize the treated patients population and the predictive factors of TIF success, identifying the subpopulation who may effectively benefit from TIF.",[26],[338,339,26],"Fundoplication","Endoscopy, Digestive System","2021-09-24",{"date":342,"type":34},"2021-10-04",{"date":344,"type":34},"2021-05-01",{"date":346,"type":22},"2029-05",{"name":348,"class":41},"IRCCS San Raffaele",{"id":350,"slug":351,"hasResults":11,"nctId":352,"briefTitle":353,"officialTitle":354,"acronym":4,"eligibilityCriteria":355,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":283,"enrollmentInfo":356,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":358,"conditions":359,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":362,"lastUpdatePostDateStruct":363,"startDateStruct":365,"completionDateStruct":367,"leadSponsor":368,"locationsCount":42},"100337163","endoscopic-fundoplication-with-muse-system-100337163","NCT03669874","Endoscopic Fundoplication With MUSE System","Clinical Application of MUSE System for Ultrasound-guided Endoscopic Fundoplication for Gastro-esophageal Reflux Disease Patients","Inclusion Criteria:\n\n* Chronic (\\> 6 months) GERD-related esophageal or extra-esophageal symptoms\n* Endoscopic or pH-impedance evidence of GERD (esophagitis, Barrett's esophagus, NERD, hypersensitive esophagus)\n* Indication to surgical fundoplication\n* Patients available for a long-term follow-up\n\nExclusion Criteria:\n\n* Hiatal hernia ≥ 3 cm\n* Major esophageal motility disorder\n* Esophageal stenosis\n* Malignant neoplasia (except minor superficial skin neoplasm)\n* Portal hypertension, bleeding disorders so to controindicate surgery, esophageal varices, stenosis or diverticula\n* Previous cardiac, thoracic or upper GI surgery\n* BMI \\>40\n* Pregnancy or breast feeding",{"count":357,"type":22},80,"This is a spontaneous, prospective, monocentric, observational, cohort study, with the aim of evaluating the effect of ultrasound-guided endoscopic fundoplication using the Medigus Ultrasonic Surgical Endostapler (MUSESystem; MediGus, Ltd. Israel) in patients with esophageal or extra-esophageal gastro-oesophageal reflux disease (GERD)-related symptoms. The end of the study will be at the end of the 6-year follow-up of the last patient enrolled. The study proposes the following objectives:\n\n* Primary objective: to evaluate the efficacy of endoscopic fundoplication with MUSE for the treatment of GERD, through clinical experience, in terms of:\n\n  * effect on GERD-Health Related Quality of Life (HRQL) and Reflux Symptom Index (RSI) questionnaire scores\n  * effect on the use and dosage of proton pump inhibitors (PPI)\n  * feasibility and safety of the endoluminal fundoplication procedure\n* Secondary objective: to characterize the treated patient population (demographic and objective data) and to identify the successful predictors of the procedure.\n\nThe study design includes the following phases:\n\n\\*Preliminary patient evaluation and verification of inclusion criteria through: Upper GI endoscopy Esophageal high-resolution manometry 24-hours esophageal pH-impedance OFF PPI PPI use GERD-HRQL and RSI questionnaires scores OFF PPI\n\n* 6-month follow-up: Upper GI endoscopy Esophageal high-resolution manometry 24-hours esophageal pH-impedance OFF PPI PPI use GERD-HRQL and RSI questionnaires scores OFF PPI\n* 12-months follow-up: Upper GI endoscopy 24-hours esophageal pH-impedance OFF PPI PPI use GERD-HRQL and RSI questionnaires scores OFF PPI\n* Yearly clinical follow-up (up to 6 years):\n\nPPI use GERD-HRQL and RSI questionnaires scores OFF PPI",[360,361],"Gastro-esophageal Reflux","Endoscopic Fundoplication","2020-12-10",{"date":364,"type":34},"2020-12-11",{"date":366,"type":34},"2015-09-16",{"date":100,"type":22},{"name":348,"class":41}]